|
Amnestic Disorder
|
0.200 |
Biomarker
|
disease |
RGD |
Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats.
|
17276409 |
2007 |
|
Reperfusion Injury
|
0.200 |
Biomarker
|
disease |
RGD |
Since facilitation of central histaminergic activity ameliorates reperfusion injury, effects of postischemic administration of L-histidine, a precursor of histamine, and thioperamide, a histamine H3 receptor antagonist, on inflammatory cell infiltration were evaluated in a rat model of transient occlusion of the middle cerebral artery.
|
17169356 |
2007 |
|
Sciatic Neuropathy
|
0.200 |
Biomarker
|
disease |
RGD |
Histaminergic involvement in neuropathic pain produced by partial ligation of the sciatic nerve in rats.
|
17350523 |
2007 |
|
Gastric ulcer
|
0.200 |
Biomarker
|
disease |
RGD |
Role of capsaicin-sensitive nerves and histamine H1, H2, and H3 receptors in the gastroprotective effect of histamine against stress ulcers in rats.
|
15680274 |
2005 |
|
Hyperemia
|
0.200 |
Biomarker
|
disease |
RGD |
The increase in the volume of blood accumulating during RH (RH-volume), the peak increase of arterial blood flow (RH-peak response) and the duration of the hyperemia (RH-duration) were used to quantify RH after occluding the anterior mesenteric artery for 30, 60 and 120 s. Hyperemia parameters were determined before and after administration of the selective histamine H3 receptor antagonist clobenpropit.
|
15381834 |
2004 |
|
Myocardial Reperfusion Injury
|
0.200 |
Biomarker
|
phenotype |
RGD |
Role of histamine H3 receptors during ischemia/reperfusion in isolated rat hearts.
|
15076218 |
2004 |
|
Visual seizure
|
0.200 |
Biomarker
|
disease |
RGD |
Intracerebroventricular administration of histamine H3 receptor antagonists decreases seizures in rat models of epilepsia.
|
15319804 |
2004 |
|
Hyperglycemia
|
0.200 |
Biomarker
|
disease |
RGD |
Effect of L-carnosine on the hyperglycemia caused by intracranial injection of 2-deoxy-D-glucose in rats.
|
11684344 |
2001 |
|
Narcolepsy
|
0.040 |
Biomarker
|
disease |
BEFREE |
Pitolisant is the first inverse agonist of the histamine H3 receptor to be prescribed for the treatment of narcolepsy with and without cataplexy.
|
31838740 |
2020 |
|
Narcolepsy
|
0.040 |
Biomarker
|
disease |
BEFREE |
Pitolisant, a selective inverse agonist for the histamine H3 receptor, is a new treatment for adults suffering from narcolepsy.
|
30771351 |
2019 |
|
Narcolepsy
|
0.040 |
Biomarker
|
disease |
BEFREE |
We assessed the safety and efficacy of pitolisant, a histamine H3 receptor inverse agonist, for treatment of cataplexy in patients with narcolepsy.
|
28129985 |
2017 |
|
Narcolepsy
|
0.040 |
Biomarker
|
disease |
BEFREE |
An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients.
|
18295497 |
2008 |
|
Impaired cognition
|
0.030 |
Biomarker
|
disease |
BEFREE |
Compound <b>3p</b> has been identified as a very promising lead, showing good Ca<sup>2+</sup> channels blockade activity (IC<sub>50</sub> = 21 ± 1 μM), potent affinity against hH3R (<i>K</i><sub>i</sub> = 565 ± 62 nM), a moderate but selective hBuChE inhibition (IC<sub>50</sub> = 7.83 ± 0.10 μM), strong antioxidant power (3.6 TE), and ability to restore cognitive impairment induced by lipopolysaccharide.
|
31724859 |
2019 |
|
Impaired cognition
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
A partial agonist and a full antagonist of the histamine H3 receptor have been suggested to have therapeutic effects on cognitive deficits in psychiatric disorders.
|
28863002 |
2018 |
|
Impaired cognition
|
0.030 |
Biomarker
|
disease |
BEFREE |
Histamine H(3) receptor antagonists are potential therapeutic agents for cognitive dysfunction, epilepsy, hypersomnia and obesity.
|
16316645 |
2006 |
|
Cataplexy
|
0.020 |
Biomarker
|
disease |
BEFREE |
Pitolisant is the first inverse agonist of the histamine H3 receptor to be prescribed for the treatment of narcolepsy with and without cataplexy.
|
31838740 |
2020 |
|
Cognition Disorders
|
0.020 |
AlteredExpression
|
group |
BEFREE |
The histamine H<sub>3</sub> receptor (Hrh3), which is expressed in many brain areas involved in alcohol drinking and alcohol reward, can be targeted with a number of drugs developed initially for cognitive disorders and/or disorders related to sleep, wakefulness, and alertness.
|
30801695 |
2020 |
|
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Search for multifunctional agents against Alzheimer's disease among non-imidazole histamine H3 receptor ligands. In vitro and in vivo pharmacological evaluation and computational studies of piperazine derivatives.
|
31271942 |
2019 |
|
Sleep Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
The Discovery of LML134, a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders.
|
30957954 |
2019 |
|
Cognition Disorders
|
0.020 |
GeneticVariation
|
group |
BEFREE |
A partial agonist and a full antagonist of the histamine H3 receptor have been suggested to have therapeutic effects on cognitive deficits in psychiatric disorders.
|
28863002 |
2018 |
|
Cataplexy
|
0.020 |
Biomarker
|
disease |
BEFREE |
We assessed the safety and efficacy of pitolisant, a histamine H3 receptor inverse agonist, for treatment of cataplexy in patients with narcolepsy.
|
28129985 |
2017 |
|
Parkinson Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
In this study, we used a mouse model of PD based on 6-hydroxydopamine (6-OHDA) to examine the effect of thioperamide, a histamine H3 receptor antagonist, on circadian activity, recognition memory and anxiety.
|
28398338 |
2017 |
|
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Histamine H3 receptor antagonists are currently being evaluated for their potential use in a number of central nervous system disorders including Alzheimer's Disease (AD).
|
19222483 |
2009 |
|
CNS disorder
|
0.020 |
Biomarker
|
group |
BEFREE |
Histamine H3 receptor antagonists are currently being evaluated for their potential use in a number of central nervous system disorders including Alzheimer's Disease (AD).
|
19222483 |
2009 |
|
CNS disorder
|
0.020 |
AlteredExpression
|
group |
BEFREE |
The successful cloning and functional expression of the histamine H(3) receptor in the late 1990 s has greatly facilitated our efforts to identify small molecule, non-imidazole based compounds to permit the evaluation of H(3) antagonists in models of CNS disorders.
|
17129577 |
2007 |